GYRE compared with YMT: revenue, margins and what each company keeps, and the suppliers and customers both name

GYREGyre Therapeutics, Inc.

Mkt capRevenueRevenue

YMTYimutian Inc.

Mkt capRevenueRevenue

Compare

GYREGyre Therapeutics, Inc.

YMTYimutian Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

rebased to 0%

GYRE, solidYMT, dashed

Supply-chain overlap

Revenue flow

GYRE: latest quarter is a loss; flow not drawable. YMT: latest quarter not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only GYRE 5

—Distributorsunlistedcustomer

—Jiangsu Wangao Pharmaceuticalsunlistedsupplier

—Nanjing Healthnice Pharmaceutical Technologyunlistedsupplier

—WuXi STAunlistedsupplier

1 more · GYRE chain ›

Shared 0

No disclosed counterparties: YMT.

Only YMT 0

None

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

GYREGyre Therapeutics, Inc.

4.43▼−6.37%· post 4.43

Mkt cap$495.1MRevenue$29MQ2 FY26Revenue$120MFY25

YMTYimutian Inc.

0.30▼−0.10%· post 0.32

ClosedNov 3 '26

Mkt cap$25.2MRevenue—Revenue—

Compare

ClosedNov 3 '26

GYREGyre Therapeutics, Inc.

YMTYimutian Inc.

4.43▼−6.37%post 4.43

Price

0.30▼−0.10%post 0.32

$495.1M

Mkt cap

$25.2M

Q2 FY26$29M

Revenue

—

FY25$120M

Revenue

—

GYRE4.43▼−6.37%vsYMT0.30▼−0.10%ClosedNov 3 '26